JP2018535196A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535196A5
JP2018535196A5 JP2018516843A JP2018516843A JP2018535196A5 JP 2018535196 A5 JP2018535196 A5 JP 2018535196A5 JP 2018516843 A JP2018516843 A JP 2018516843A JP 2018516843 A JP2018516843 A JP 2018516843A JP 2018535196 A5 JP2018535196 A5 JP 2018535196A5
Authority
JP
Japan
Prior art keywords
amino acid
heavy chain
domain
antibody
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018516843A
Other languages
English (en)
Japanese (ja)
Other versions
JP7239320B2 (ja
JP2018535196A (ja
Filing date
Publication date
Priority claimed from EP15188060.6A external-priority patent/EP3150637A1/en
Application filed filed Critical
Priority claimed from PCT/EP2016/073410 external-priority patent/WO2017055539A1/en
Publication of JP2018535196A publication Critical patent/JP2018535196A/ja
Publication of JP2018535196A5 publication Critical patent/JP2018535196A5/ja
Application granted granted Critical
Publication of JP7239320B2 publication Critical patent/JP7239320B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018516843A 2015-10-02 2016-09-30 多重特異性抗体 Active JP7239320B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15188060.6 2015-10-02
EP15188060.6A EP3150637A1 (en) 2015-10-02 2015-10-02 Multispecific antibodies
EP16168918.7 2016-05-10
EP16168918 2016-05-10
PCT/EP2016/073410 WO2017055539A1 (en) 2015-10-02 2016-09-30 Multispecific antibodies

Publications (3)

Publication Number Publication Date
JP2018535196A JP2018535196A (ja) 2018-11-29
JP2018535196A5 true JP2018535196A5 (cg-RX-API-DMAC7.html) 2019-11-07
JP7239320B2 JP7239320B2 (ja) 2023-03-14

Family

ID=57068100

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516843A Active JP7239320B2 (ja) 2015-10-02 2016-09-30 多重特異性抗体

Country Status (5)

Country Link
US (2) US20170129962A1 (cg-RX-API-DMAC7.html)
EP (1) EP3356420B1 (cg-RX-API-DMAC7.html)
JP (1) JP7239320B2 (cg-RX-API-DMAC7.html)
CN (1) CN108290958B (cg-RX-API-DMAC7.html)
WO (1) WO2017055539A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3224275B1 (en) 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
EP3973980A1 (en) 2015-03-31 2022-03-30 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3150636A1 (en) * 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN110382529B (zh) 2017-03-02 2024-03-08 诺华股份有限公司 工程化的异源二聚体蛋白质
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
EA202091053A1 (ru) * 2018-01-15 2020-12-03 Ай-Маб Биофарма Юэс Лимитед Модифицированные c- и ch1-домены
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
WO2019183406A1 (en) * 2018-03-21 2019-09-26 Invenra Inc. Multispecific antibody purification with ch1 resin
JP7541930B2 (ja) 2018-06-29 2024-08-29 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ１抗体およびその使用
US20220089722A1 (en) * 2018-12-29 2022-03-24 Nantong Yichen Biopharma. Co. Ltd. Heterodimeric fusion protein
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2023208426A1 (en) 2022-01-24 2024-07-25 Novimmune Sa Composition and methods for the selective activation of cytokine signaling pathways
EP4493592A1 (en) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
WO2023178357A1 (en) * 2022-03-18 2023-09-21 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
WO2023201333A1 (en) 2022-04-14 2023-10-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies to ebola virus glycoprotein and their use
AU2023268051A1 (en) 2022-05-13 2025-01-02 BioNTech SE Rna compositions targeting hiv
IL321437A (en) * 2022-12-14 2025-08-01 Evolveimmune Therapeutics Inc Bispecific antibody fusion molecules and methods for using them
WO2024138151A1 (en) 2022-12-22 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
EP4642797A1 (en) 2022-12-28 2025-11-05 BioNTech SE Rna compositions targeting hiv
CN121866336A (zh) 2023-08-03 2026-04-14 百欧恩泰欧洲股份公司 靶向hiv的rna组合物
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
WO2025098100A1 (en) * 2023-11-07 2025-05-15 Biomap (Suzhou) Intelligent Technology Limited Modified polypeptides for heteromultimer
WO2026068864A1 (en) 2024-09-30 2026-04-02 BioNTech SE Engineered ch1 and cl domains for the prevention of chain mispairing

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE102005028778A1 (de) * 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US7642282B2 (en) * 2007-01-19 2010-01-05 Milliken & Company Whitening agents for cellulosic substrates
JP6157046B2 (ja) * 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
BR112013023918A2 (pt) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
KR101261949B1 (ko) * 2011-05-13 2013-05-13 현대자동차주식회사 촉매유닛
US8901853B2 (en) * 2012-07-11 2014-12-02 Analog Devices, Inc. Multi-string LED drive system
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CA2932547C (en) * 2014-01-06 2023-05-23 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules

Similar Documents

Publication Publication Date Title
JP2018535196A5 (cg-RX-API-DMAC7.html)
JP2017522888A5 (cg-RX-API-DMAC7.html)
JP2022088627A (ja) 多重特異性および多機能性分子ならびにその使用
JP2020122013A5 (cg-RX-API-DMAC7.html)
US9771425B2 (en) Anti-PD-1 antibodies
JP2023100868A (ja) 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
JP2022523197A (ja) Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
JP2022521750A (ja) カルレティキュリンに結合する多機能性分子およびその使用
CN112955465A (zh) 抗tcr抗体分子及其用途
CN110520445B (zh) 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备
JP2020023523A5 (cg-RX-API-DMAC7.html)
JP2019531725A (ja) ラムダ及びカッパ軽鎖を含む多重特異性抗体分子
IL269270B (en) Method and preparations for cellular immunotherapy
JP2019527543A5 (cg-RX-API-DMAC7.html)
EP3707162A1 (en) Il2rbeta/common gamma chain antibodies
JP2019536430A5 (cg-RX-API-DMAC7.html)
WO2020094834A1 (en) Il2rbeta/common gamma chain antibodies
TW201815825A (zh) 經修飾之抗原結合fab片段及包含其之抗原結合分子
JP2018512856A5 (cg-RX-API-DMAC7.html)
CA3164972A1 (en) Materials and methods for in vivo biological targeting
CN115397852B (zh) 工程化抗il-2抗体
JP2019530431A5 (cg-RX-API-DMAC7.html)
JP2018521691A5 (cg-RX-API-DMAC7.html)
RU2012118636A (ru) Молекула, специфически связывающаяся с rsv
JP2024515591A (ja) Ｔｃｒに結合する多機能性分子およびその使用